These deletions encompass a CTCF binding site and experimental disruption of this site led to increased IRX3 expression in IRX3negative PF-382 T-ALL cells though an enhancer hijacking mechanism, with expanded contacts with the CRNDE-IRX5 locus which is strongly acetylated during normal T cell development.34 The gene discussed is IRX3; the disease is acute lymphoblastic leukemia.